Cost is the number-one reason people who qualify for GLP-1 medications never start them. If you've looked up the price of Wegovy or Ozempic and felt the sticker shock, you're not alone — and you're also not out of options.
This article breaks down exactly what semaglutide costs at retail, how insurance coverage works (and where it falls short), what manufacturer savings programs actually offer, and why physician-supervised telehealth is increasingly the most practical path for patients without comprehensive coverage.
Note: Drug prices change frequently. The figures in this article reflect publicly available list prices as of 2026. Actual costs depend on your pharmacy, insurance plan, and any applicable savings programs. This article is for educational purposes only and does not constitute medical or financial advice.
Retail Prices: What Semaglutide Costs Without Insurance
Semaglutide is sold under two brand names in the United States: Ozempic (approved for type 2 diabetes) and Wegovy (approved for chronic weight management). Both contain the same active molecule, but they are prescribed at different doses for different indications.
Without insurance or any discount program, the monthly list price is significant:
| Medication | Brand Name | Approved For | Est. Monthly Cost (List) |
|---|---|---|---|
| Semaglutide 2.4 mg/wk | Wegovy | Weight management | ~$1,350–$1,450/mo |
| Semaglutide 0.5–2 mg/wk | Ozempic | Type 2 diabetes | ~$935–$1,010/mo |
| Tirzepatide 2.5–15 mg/wk | Mounjaro | Type 2 diabetes | ~$1,060–$1,180/mo |
| Tirzepatide 2.5–15 mg/wk | Zepbound | Weight management | ~$1,060–$1,180/mo |
These are list prices — what you'd pay at a retail pharmacy without any insurance benefit or savings card. The actual price you pay depends heavily on your coverage.
How Insurance Coverage Works for GLP-1 Medications
Insurance coverage for GLP-1 drugs is inconsistent and often frustrating. Here's a realistic picture:
Medicare
Medicare Part D currently does not cover GLP-1 drugs prescribed for weight loss. It may cover Ozempic if you have a type 2 diabetes diagnosis, but Wegovy and Zepbound — which are approved specifically for chronic weight management — are excluded under most Part D plans. This is a significant coverage gap affecting millions of Medicare beneficiaries.
Medicaid
Medicaid coverage varies by state. Some states cover FDA-approved anti-obesity medications; many do not. Coverage is also subject to prior authorization requirements and may exclude certain brand-name formulations.
Commercial (Employer-Sponsored) Insurance
This is where coverage is most likely, but still far from guaranteed. A 2024 KFF analysis found that fewer than half of large employer plans cover anti-obesity medications. When coverage exists, you typically still pay a copay or coinsurance (often $50–$200/month after meeting your deductible).
| Insurance Type | Coverage for Weight Loss GLP-1s | Typical Out-of-Pocket |
|---|---|---|
| Medicare Part D | Not covered | Full list price |
| Medicaid | State-dependent | $0–full price |
| Employer plan (covers obesity drugs) | Covered | $50–$200/mo after deductible |
| Employer plan (no obesity drug benefit) | Not covered | Full list price |
| ACA Marketplace plans | Varies by plan | $0–full price |
The most reliable way to find out your actual coverage is to call the member services number on your insurance card and ask specifically: "Does my plan cover Wegovy or Zepbound for chronic weight management? What are the prior authorization requirements?"
Manufacturer Savings Programs
Both Novo Nordisk (maker of Wegovy and Ozempic) and Eli Lilly (maker of Mounjaro and Zepbound) offer savings programs for commercially insured patients. These are not available to Medicare or Medicaid beneficiaries.
Novo Nordisk (Wegovy / Ozempic)
The Wegovy Savings Offer can reduce out-of-pocket costs to as low as $0/month for eligible, commercially insured patients, up to an annual cap. Uninsured patients may access a separate program but typically with a higher monthly floor. Eligibility and terms change — always check the official Novo Nordisk patient assistance page directly.
Eli Lilly (Zepbound / Mounjaro)
Lilly's savings programs for Zepbound and Mounjaro follow a similar structure: commercially insured patients may pay as little as $25–$50/month. Lilly also offers a direct-pay option called Zepbound vials (a multi-use vial format) at a lower list price than the auto-injector pens — an important option for uninsured patients.
Key limitation: These savings programs apply only to commercially insured patients. If you have Medicare, Medicaid, or no insurance, manufacturer savings cards do not apply. You must use them through a participating retail pharmacy.
GoodRx and Pharmacy Discount Programs
GoodRx and similar pharmacy discount programs (RxSaver, SingleCare, NeedyMeds) can reduce the retail price of some medications dramatically — but GLP-1 injectables are expensive enough that discounts rarely bring costs below $800–$900/month. These programs are most useful as a fallback when manufacturer programs don't apply.
Worth checking: the GoodRx price for your specific medication at your specific pharmacy, since prices vary by location. But don't expect the same 70–80% discount that applies to generic medications.
Telehealth as a Cost-Effective Path
Physician-supervised telehealth has changed the economics of GLP-1 access meaningfully. Here's why:
Lower Overhead, Transparent Pricing
Telehealth platforms eliminate the cost layers of traditional obesity medicine practices — physical offices, in-person scheduling, specialist referral cycles. That cost reduction can be passed on to patients.
Physician Supervision Without the Markup
Board-certified physicians reviewing your assessment and prescribing appropriate medications is the same level of clinical oversight you'd get in person — without the specialist billing rates. At PropPilot, physician consultation and ongoing supervision is included in one flat monthly fee.
Pharmacy Optimization
Telehealth providers often work with partner pharmacies that offer competitive pricing on GLP-1 medications, separate from manufacturer savings cards. This matters for patients without insurance coverage who are paying out of pocket.
| Access Path | Physician Supervision | Estimated Monthly Cost | Insurance Needed? |
|---|---|---|---|
| In-person obesity medicine specialist | Yes | $200–$500+ (visits) + medication | Often required |
| Primary care (with coverage) | Yes | $50–$200 (copay) + med copay | Yes |
| Primary care (no coverage) | Yes | $150–$300 (visit) + full med price | No |
| PropPilot telehealth | Yes | $199/mo (consultation included) | No |
| No supervision (black market / unapproved) | No | Variable | No |
The telehealth path is not universally cheaper — if you have comprehensive insurance coverage that covers both the visit and the medication, your out-of-pocket with your existing PCP may be lower. The advantage of telehealth is access: no referrals, no waitlists, 24-hour physician turnaround, and transparent flat-rate pricing.
See If You Qualify for Physician-Supervised GLP-1 Treatment
Complete a free eligibility assessment. Board-certified physicians review your profile and respond within 24 hours.
Start Free AssessmentWhat to Watch Out For: Common Cost Mistakes
Assuming "Off-Label" Means Cheaper
You may see Ozempic prescribed off-label for weight loss at a lower dose than Wegovy. While Ozempic has a lower list price, this approach carries its own considerations: it may not be covered by insurance for a weight-loss indication, and the dose may differ from what clinical trials used for weight management. Always discuss this with your physician.
Compounded Semaglutide
During periods of supply shortage, the FDA has allowed compounding pharmacies to produce semaglutide. These compounded versions are significantly cheaper but are not FDA-approved and are not the same as the branded medication. The regulatory status of compounded GLP-1s changes frequently. As of 2026, the FDA has removed semaglutide from its shortage list, which limits the legal availability of compounded versions. Do not use compounded medications without explicit guidance from a licensed physician.
Stopping Too Early Due to Cost
GLP-1 medications are most effective when used as part of a sustained treatment plan. Stopping and restarting due to cost gaps is associated with worse outcomes. If cost is a concern, it's worth discussing a full financial picture with your physician before starting — including what happens if your insurance situation changes.
The Bottom Line
Semaglutide's retail cost without insurance is high — typically $935–$1,450/month depending on the brand and dose. But "without insurance" is rarely the full picture. Between manufacturer savings programs for commercially insured patients, pharmacy discount programs, and telehealth's flat-rate model, the range of what patients actually pay is much wider.
The most important first step: understand your specific coverage situation before assuming the full retail price applies to you. If you don't have commercial insurance that covers anti-obesity medications, physician-supervised telehealth like PropPilot offers a predictable, medically sound path at a fraction of the specialist-visit-plus-medication cost. PropPilot works with board-certified, licensed physicians who prescribe only FDA-approved GLP-1 medications. Treatment requires a live video consultation; you can review our Telehealth Consent and Privacy Policy before starting.
Medical Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Drug prices, insurance coverage rules, and manufacturer savings programs change frequently — verify current details directly with your insurer and pharmacy. GLP-1 medications require a prescription from a licensed physician. Not all patients are appropriate candidates. Results may vary. Consult a qualified healthcare provider before starting any new medication or weight loss program.